342 related articles for article (PubMed ID: 28851294)
1. Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.
Thorlund K; Horwitz MS; Fife BT; Lester R; Cameron DW
BMC Infect Dis; 2017 Aug; 17(1):595. PubMed ID: 28851294
[TBL] [Abstract][Full Text] [Related]
2. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
3. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill.
Kristoff J; Rinaldo CR; Mailliard RB
Viruses; 2019 Dec; 12(1):. PubMed ID: 31905690
[TBL] [Abstract][Full Text] [Related]
4. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
[TBL] [Abstract][Full Text] [Related]
5. HIV latency reversal agents: A potential path for functional cure?
Lopes JR; Chiba DE; Dos Santos JL
Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies to deplete the HIV reservoir.
Archin NM; Margolis DM
Curr Opin Infect Dis; 2014 Feb; 27(1):29-35. PubMed ID: 24296585
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J;
Lancet; 2020 Mar; 395(10227):888-898. PubMed ID: 32085823
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
9. Curing HIV by 'kick and kill': from theory to practice?
Pace M; Frater J
Expert Rev Anti Infect Ther; 2019 Jun; 17(6):383-386. PubMed ID: 31071275
[No Abstract] [Full Text] [Related]
10. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.
Macedo AB; Novis CL; Bosque A
Front Immunol; 2019; 10():2450. PubMed ID: 31681325
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation.
Wang YK; Wei L; Hu W; Yu PX; Li Z; Yu HP; Li X
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615199
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 functional cure: will the dream come true?
Liu C; Ma X; Liu B; Chen C; Zhang H
BMC Med; 2015 Nov; 13():284. PubMed ID: 26588898
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
15. Selective BCL-X
Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
[TBL] [Abstract][Full Text] [Related]
16. Current views on HIV-1 latency, persistence, and cure.
Melkova Z; Shankaran P; Madlenakova M; Bodor J
Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
[TBL] [Abstract][Full Text] [Related]
17. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
18. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
[TBL] [Abstract][Full Text] [Related]
19. Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; Cruz CRY; Jones RB; Lynch RM; Sweeney EE; Fernandes R
Int J Nanomedicine; 2023; 18():4055-4066. PubMed ID: 37520301
[TBL] [Abstract][Full Text] [Related]
20. Finding a cure for HIV: will it ever be achievable?
Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
